(Metformin hydrochloride + vildagliptin) is a Small Molecule owned by Novartis, and is involved in 18 clinical trials, which were completed.
Metformin administration also increases AMPK activity in skeletal muscle. AMPK is known to cause GLUT4 deployment to the plasma membrane, resulting in insulin-independent glucose uptake.
Vildagliptin acts primarily by inhibiting DPP-4, the enzyme responsible for the degradation of the incretin hormones GLP-1 (glucagon-like peptide-1) and GIP (glucose-dependent insulinotropic polypeptide). Where as metformin is a biguanide with antihyperglycaemic effects, lowering both basal and postprandial plasma glucose.
The revenue for (Metformin hydrochloride + vildagliptin) is expected to reach a total of $2.2bn through 2038. This change impacts the valuation of this asset and is an important factor to understand the current value of the drug in a clinical process. View the complete picture with the (Metformin hydrochloride + vildagliptin) NPV Report.
(Metformin hydrochloride + vildagliptin) Overview
Metformin Hydrochloride and vildagliptin (Eucreas, Icandra, Zomarist, Galvus Met, Galvumet, Sobrea, Jalra Met, Vysov Met) is a fixed dose combination anti-diabetic agent. It is formulated as film coated tablets and tablets for oral route of administration. It is indicated in the treatment of type 2 diabetes mellitus. It is indicated in the treatment of adult patients who are unable to achieve sufficient glycaemic control at their maximally tolerated dose of oral metformin alone or who are already treated with the combination of vildagliptin and metformin as separate tablets. It is indicated in combination with a sulphonylurea (i.e. triple combination therapy) as an adjunct to diet and exercise in adult patients inadequately controlled with metformin and a sulphonylurea. It is indicated in triple combination therapy with insulin as an adjunct to diet and exercise to improve glycaemic control in adult patients when insulin at a stable dose and metformin alone do not provide adequate glycaemic control. The drug combination was under development for the treatment of type 2 diabetes in Japan.
Sumitomo Pharma Overview
Sumitomo Pharma, a subsidiary of Sumitomo Chemical Co Ltd develops, manufactures, sells, imports and exports pharmaceutical products. The company drugs are focused on major therapeutic areas which include regenerative diseases, oncology, psychiatry and neurology and infectious diseases. It also offers veterinary medicines for companion animals, primarily dogs, and cats, as well as for livestock such as cattle, swine, poultry, horses, and aquacultured fish. It also offers food additives, chemical product materials, food ingredients, and other products. Sumitomo Dainippon has research laboratories and manufacturing and distribution facilities in Japan. The company operates through subsidiaries and offices in North America, Europe, and Asia Pacific. Sumitomo Pharma is headquartered in Osaka, Japan.
The company reported revenues of (Yen) JPY560,035 million for the fiscal year ended March 2022 (FY2022), an increase of 8.5% over FY2021. In FY2022, the company’s operating margin was 10.8%, compared to an operating margin of 13.8% in FY2021. In FY2022, the company recorded a net margin of 10.1%, compared to a net margin of 10.9% in FY2021. The company reported revenues of JPY159,413 million for the second quarter ended September 2022, a decrease of 0.3% over the previous quarter.
Quick View – (Metformin hydrochloride + vildagliptin)
|Highest Development Stage|